Biodexa Pharmaceuticals PLC F-1 registration statements

Biodexa Pharmaceuticals PLC has filed a pre-effective amendment to its Form F-1 registration statement, detailing the resale of ordinary shares represented by American Depositary Shares by selling shareholders.

Biodexa Pharmaceuticals PLC has filed an F-1 registration statement detailing the resale of ordinary shares represented by American Depositary Shares by selling shareholders.

Biodexa Pharmaceuticals PLC has filed an F-1/A registration statement for a best efforts public offering of up to 4,422,604 Units, aiming to raise approximately $15.5 million in net proceeds to fund development programs and for general corporate purposes.

Biodexa Pharmaceuticals PLC filed an Amendment No. 1 to its F-1 Registration Statement for a best efforts public offering of up to 3,536,345 Units, aiming to raise up to $18.0 million for development programs and working capital.

Biodexa Pharmaceuticals PLC is registering a public offering of up to $18 million in units, including American Depositary Shares and Series L Warrants, to fund its clinical development programs.

Biodexa Pharmaceuticals seeks to raise up to $35 million through an equity line of credit with C/M Capital Master Fund, LP, involving the potential sale of ordinary shares represented by American Depositary Shares.

Biodexa Pharmaceuticals is registering for resale 4,349,102,800 ordinary shares, represented by 10,872,757 American Depositary Shares, by selling shareholders.

Biodexa Pharmaceuticals is registering for resale up to 2,486,270,400 ordinary shares represented by 6,215,676 American Depositary Shares by selling shareholders.

Biodexa Pharmaceuticals is registering for the resale of approximately $3.9 million worth of ordinary shares through depositary shares by existing shareholders.